Tenofovir disoproxil phosphate

Developing acute hepatitis B in immunocompetent non-responders to hepatitis B vaccination has been rarely reported. We report such a case in a 79 year old heterosexual male. There is evidence that tenofovir disoproxil/emtricitabine as primary prophylaxis can prevent acquisition of hepatitis B. In the current era of HIV pre-exposure prophylaxis (PrEP) with tenofovir disoproxil/emtricitabine, there is dual benefit of preventing HIV and hepatitis B. We discuss the importance of considering tenofovir disoproxil/emtricitabine pre-exposure prophylaxis in those hepatitis B vaccination non-responders at high risk of acquiring hepatitis B.

This article is about long-term use of tenofovir disoproxil fumarate increases fracture risk in elderly patients with chronic hepatitis B which was published in a recent issue of the Journal of Hepatol.This topic is particularly intriguing as it explores the impact of entecavir (ETV) and tenofovir disoproxil (TDF) on the risk of bone fracture in patients with chronic hepatitis B based on a real-world territory-wide cohort.Their findings revealed that long-term TDF treatment for 2 years or more is associated with a higher incidence of bone fracture in older patients.Although this study was elegantly designed and inspiring, we believe that certain aspects warrant further discussion.Addnl., individuals with osteosarcopenia are significantly more likely to experience falls, fractures, and mortality than in non-osteosarcopenic groups.Therefore, this information is imperative for the readers knowledge, and baseline variables which should include bone mineral d. and sarcopenia index prior to the antiviral treatments are needed to draw a robust conclusion.Secondly, they noted that TDF-treated patients with a match were older and more likely to be female, as per the propensity score-matching.Here authors discovered that patients receiving TDF had a higher risk of developing incident fractures compared to those treated with ETV after 24 mo (weighted subdistribution hazard ratio 2.33, 95% CI 1.20 - 4.55, p = 0.014 for age > 65 years; weighted subdistribution hazard ratio 2.12, 95% CI 1.01 - 4.46, p = 0.047 for age > 70 years).Similarly, age and sex could both be risk factors for osteoporosis and fracture, which occur as part of the natural aging process, particularly in relation to menopause and the alterations in sex hormones that accompany advancing age.In order to further validate whether long-term use of TDF increases the risk of fractures in elderly patients with chronic hepatitis B, it is advisable to ensure consistency in terms of phys. activity intensity and diet composition between the two groups.In conclusion, while acknowledging the aforementioned points that merit careful consideration, we are genuinely grateful for the contribution of Yip et al. in their work, and their fi ndings support the current treatment guidelines, advocating for the customization of antiviral therapy based on age and comorbidities.